Indium Dtpa (In111) Curium Netherlands

Indium-111 DTPA, the active ingredient in Indium Dtpa (In111) Curium Netherlands, is a diagnostic radiopharmaceutical presented as a diagnostic kit for radiolabeling for intrathecal use. It enables imaging of cerebrospinal fluid pathways and detection of CSF leaks in patients undergoing diagnostic evaluation.

GNH USA supplies Indium Dtpa (In111) Curium Netherlands as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Indium-111 DTPA is employed in diagnostic imaging of cerebrospinal fluid pathways.

Cerebrospinal fluid flow studies: assesses CSF circulation and identifies blockages. Detection of CSF leaks: localizes sites of spinal or cranial cerebrospinal fluid leakage. Post‑operative CSF assessment: evaluates CSF dynamics after neurosurgical procedures.

Adverse reactions may occur following intrathecal administration of Indium-111 DTPA.

Common Side Effects: - Headache: mild to moderate discomfort after lumbar puncture. - Nausea: transient feeling of queasiness. - Back pain: mild soreness at puncture site. - Transient fever: low‑grade temperature rise. - Lumbar puncture site discomfort: localized irritation. - Mild hypotension: temporary blood pressure drop.

Serious or Rare Side Effects: - Allergic reaction or anaphylaxis: severe hypersensitivity requiring immediate care. - Severe meningitis: infection of the central nervous system. - Radiation‑induced myelopathy: rare spinal cord injury from radiation exposure. - CSF infection: bacterial contamination of the intrathecal space. - Severe neurological deficit: unexpected loss of function following injection.

Proper handling and patient monitoring are essential when using this radiopharmaceutical.

Verify radiolabeling integrity: confirm correct activity before administration. Maintain sterile technique: use aseptic procedures for intrathecal injection. Assess patient allergy history: screen for hypersensitivity to DTPA or indium. Monitor vital signs post‑procedure: observe for hemodynamic changes. Implement radiation safety measures: protect staff and environment from exposure. Store at ambient temperature: keep in original shielded container, protect from light and moisture.

Indium-111 DTPA may interact with other agents that affect imaging quality or patient safety.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals with overlapping gamma emissions: may obscure imaging results. - High‑dose iodine contrast agents: can interfere with gamma detection. - Strong chelating agents (e.g., EDTA): may strip indium from DTPA.

Moderate Interactions (Monitor Closely): - Anticoagulants: increase risk of bleeding from lumbar puncture. - CNS depressants: may mask neurologic symptoms. - Immunosuppressants: elevate infection risk after intrathecal administration.